Biontech SE
BNTX99.710USD
+3.170+3.28%
收盘 11/25, 16:00（美东）报价延迟15分钟
23.98B总市值
亏损市盈率 TTM
关于 Biontech SE 公司
BioNTech SE 是一家位于德国的临床阶段生物技术公司。该公司专注于针对癌症和其他严重疾病的患者特异性免疫疗法。该公司提供的技术包括基于 mRNA 的疗法、细胞疗法、小分子和抗体，这些技术可用于特定目的，甚至可以以协同方式相互结合。该公司还利用不同的科学方法和技术平台开发了广泛的产品线，包括个性化的基于 mRNA 的产品候选物、嵌合抗原受体 T 细胞、检查点免疫调节剂、靶向癌症抗体和小分子。此外，该公司还为其他治疗领域提供诊断产品和药物发现服务，包括传染病、过敏和自身免疫性疾病。
Biontech SE简介
公司代码BNTX
公司名称Biontech SE
上市日期Oct 10, 2019
CEOProf. Ugur Sahin, M.D.
员工数量6772
证券类型Depository Receipt
年结日Oct 10
公司地址An der Goldgrube 12
城市MAINZ
上市交易所NASDAQ Global Select Consolidated
国家Germany
邮编55131
电话4949613190840
网址https://www.biontech.com/
公司代码BNTX
上市日期Oct 10, 2019
CEOProf. Ugur Sahin, M.D.
Biontech SE公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
767.54K
+1.69%
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
790.00
--
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
Mr. Ramon Zapata Gomez
Mr. Ramon Zapata Gomez
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Helmut Jeggle
Mr. Helmut Jeggle
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
--
--
Dr. Oezlem Tuereci, M.D.
Dr. Oezlem Tuereci, M.D.
Chief Medical Office, Member of the Management Board
Chief Medical Office, Member of the Management Board
--
--
Ms. Baroness Nicola Blackwood
Ms. Baroness Nicola Blackwood
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Ms. Annemarie Hanekamp
Ms. Annemarie Hanekamp
Member of the Management Board, Chief Commercial Officer
Member of the Management Board, Chief Commercial Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
767.54K
+1.69%
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
790.00
--
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
Mr. Ramon Zapata Gomez
Mr. Ramon Zapata Gomez
Chief Financial Officer
Chief Financial Officer
--
--
收入明细
单位: USD更新时间: 3月12日 周三
单位: USD更新时间: 3月12日 周三
FY2019
FY2018
FY2017
业务USD
名称
营收
占比
Collaboration Revenue
84.43M
77.75%
Revenues from Other Sales Transactions
24.16M
22.25%
由于公司未披露，未能获取相关数据
业务
地区
业务USD
名称
营收
占比
Collaboration Revenue
84.43M
77.75%
Revenues from Other Sales Transactions
24.16M
22.25%
股东统计
更新时间: 11月15日 周六
更新时间: 11月15日 周六
持股股东
股东类型
持股股东
持股股东
占比
AT Impf GmbH
42.36%
Medine GmbH
16.69%
Baillie Gifford & Co.
3.28%
Fidelity Management & Research Company LLC
2.07%
T. Rowe Price Investment Management, Inc.
2.01%
其他
33.60%
持股股东
持股股东
占比
AT Impf GmbH
42.36%
Medine GmbH
16.69%
Baillie Gifford & Co.
3.28%
Fidelity Management & Research Company LLC
2.07%
T. Rowe Price Investment Management, Inc.
2.01%
其他
33.60%
股东类型
持股股东
占比
Corporation
59.74%
Investment Advisor
15.59%
Investment Advisor/Hedge Fund
3.82%
Individual Investor
2.11%
Research Firm
1.19%
Hedge Fund
1.05%
Sovereign Wealth Fund
0.63%
Bank and Trust
0.22%
Pension Fund
0.18%
其他
15.49%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
793
55.39M
23.04%
-2.63M
2025Q2
815
205.26M
85.38%
-4.32M
2025Q1
851
205.71M
85.57%
-4.55M
2024Q4
869
205.33M
85.56%
+3.19M
2024Q3
843
197.46M
82.52%
-2.61M
2024Q2
819
194.42M
81.78%
-7.50M
2024Q1
835
193.57M
81.42%
-10.02M
2023Q4
897
193.24M
81.29%
-7.90M
2023Q3
920
192.71M
79.62%
-7.47M
2023Q2
940
195.49M
80.61%
-8.54M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
AT Impf GmbH
101.85M
42.37%
-636.54K
-0.62%
Dec 31, 2024
Medine GmbH
40.13M
16.69%
-304.48K
-0.75%
Mar 31, 2025
Baillie Gifford & Co.
8.04M
3.34%
-120.81K
-1.48%
Jun 30, 2025
Fidelity Management & Research Company LLC
6.98M
2.9%
+1.02M
+17.22%
Jun 30, 2025
T. Rowe Price Investment Management, Inc.
3.60M
1.5%
+3.51M
+4076.79%
Jun 30, 2025
Flossbach von Storch AG
4.23M
1.76%
-29.53K
-0.69%
Jun 30, 2025
PRIMECAP Management Company
4.00M
1.66%
-44.96K
-1.11%
Jun 30, 2025
Dodge & Cox
877.44K
0.36%
+877.44K
--
Jun 30, 2025
Sahin (Ugur MD)
2.05M
0.85%
-724.50K
-26.11%
Mar 31, 2025
Pfizer Inc
3.66M
1.52%
--
--
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月6日 周四
更新时间: 11月6日 周四
机构名称
占比
Langar Global HealthTech ETF
3.74%
iShares Genomics Immunology and Healthcare ETF
3.63%
Global X Genomics & Biotechnology ETF
3.06%
First Trust NYSE Arca Biotechnology Index Fund
2.71%
VanEck Biotech ETF
2.39%
Franklin Genomic Advancements ETF
2.28%
Virtus LifeSci Biotech Products ETF
1.57%
WisdomTree BioRevolution Fund
1.43%
ProShares Ultra Nasdaq Biotechnology
1.02%
Invesco Nasdaq Biotechnology ETF
1%
查看更多
Langar Global HealthTech ETF
占比3.74%
iShares Genomics Immunology and Healthcare ETF
占比3.63%
Global X Genomics & Biotechnology ETF
占比3.06%
First Trust NYSE Arca Biotechnology Index Fund
占比2.71%
VanEck Biotech ETF
占比2.39%
Franklin Genomic Advancements ETF
占比2.28%
Virtus LifeSci Biotech Products ETF
占比1.57%
WisdomTree BioRevolution Fund
占比1.43%
ProShares Ultra Nasdaq Biotechnology
占比1.02%
Invesco Nasdaq Biotechnology ETF
占比1%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
Biontech SE的前五大股东是谁？
Biontech SE 的前五大股东如下：
AT Impf GmbH持有股份：101.85M，占总股份比例：42.37%。
Medine GmbH持有股份：40.13M，占总股份比例：16.69%。
Baillie Gifford & Co.持有股份：8.04M，占总股份比例：3.34%。
Fidelity Management & Research Company LLC持有股份：6.98M，占总股份比例：2.90%。
T. Rowe Price Investment Management, Inc.持有股份：3.60M，占总股份比例：1.50%。
AT Impf GmbH持有股份：101.85M，占总股份比例：42.37%。
Medine GmbH持有股份：40.13M，占总股份比例：16.69%。
Baillie Gifford & Co.持有股份：8.04M，占总股份比例：3.34%。
Fidelity Management & Research Company LLC持有股份：6.98M，占总股份比例：2.90%。
T. Rowe Price Investment Management, Inc.持有股份：3.60M，占总股份比例：1.50%。
Biontech SE的前三大股东类型是什么？
Biontech SE 的前三大股东类型分别是：
AT Impf GmbH
Medine GmbH
Baillie Gifford & Co.
AT Impf GmbH
Medine GmbH
Baillie Gifford & Co.
有多少机构持有Biontech SE(BNTX)的股份？
截至2025Q3，共有793家机构持有Biontech SE的股份，合计持有的股份价值约为55.39M，占公司总股份的23.04%。与2025Q2相比，机构持股有所增加，增幅为-62.34%。
哪个业务部门对Biontech SE的收入贡献最大？
在FY2019，Collaboration Revenue业务部门对Biontech SE的收入贡献最大，创收84.43M，占总收入的77.75%。
